3,7-Dimethyl-1-(2-oxopropyl)xanthine | 10244-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3,7-Dimethyl-1-(2-oxopropyl)xanthine
• 英文别名: 3,7-dimethyl-1-(2-oxo-propyl)-3,7-dihydro-purine-2,6-dione；1-acetonyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione；1-Acetonyl-3,7-dimethyl-3,7-dihydro-purin-2,6-dion；3,7-dimethyl-1-(2-oxopropyl)purine-2,6-dione
• CAS: 10244-22-1
• 化学式: C₁₀H₁₂N₄O₃
• 分子量: 236.23
• InChiKey: NMMVOJOKARYAHF-UHFFFAOYSA-N

物化性质

• 熔点：
  167 °C
• 沸点：
  477.6±51.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  75.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,7-Dimethyl-1-(2-oxopropyl)xanthine 在 sodium tetrahydroborate 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 氟氯西林
  参考文献：
  名称：

  Potentiation of cADPR-Induced Ca²⁺-Release by Methylxanthine Analogues

  摘要：

  Caffeine and other methylxanthines are known to induce Ca2+-release from intracellular stores via the ryanodine receptor. In the present work, a range of caffeine analogues, in which methyl groups at the 1 and 7 positions were replaced with alkyl chains containing different functional groups (oxo, hydroxyl, propargyl, ester, and acids), were synthesized. These compounds were then screened for their ability to potentiate Ca2+-release induced by cADPR (an endogenous modulator of ryanodine receptors) in sea urchin egg homogenates. Two of the synthesized methylxanthines, 1,3-dimethyl-7-(7-hydroxyoctyl)xanthine (37) and 3-methyl-7-(7-oxooctyl)-1-propargylxanthine (66), were shown to be more potent than caffeine in potentiating cADPR-induced Ca2+-release, while 1,3-dimethyl-7-(5-ethylcarboxypentyl)xanthine (14) was shown to be more efficacious. The development of new methylxanthine analogues may lead to a better understanding of ryanodine receptor function and could possibly provide novel therapeutic agents.

  DOI：

  10.1021/jm980469t
• 作为产物：
  描述：

  可可碱 、 溴丙酮 在 sodium hydroxide 作用下， 以 异丙醇 为溶剂， 反应 24.0h， 生成 3,7-Dimethyl-1-(2-oxopropyl)xanthine
  参考文献：
  名称：

  Highly efficient C-8 oxidation of substituted xanthines with substitution at the 1-, 3-, and 7- positions using biocatalysts

  摘要：

  由克雷伯氏菌属和红球菌属菌株组成的细菌群能将 1-、3- 和 7-取代的黄嘌呤定量转化为各自的 8-氧代化合物。

  DOI：

  10.1039/a900089e

文献信息

• Advanced formulations and therapies for treating hard-to-heal wounds
  申请人：Kopacki Matthew H.

  公开号：US10864214B2

  公开（公告）日：2020-12-15

  A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.

  一种愈合难愈合伤口的方法，包括以下步骤：在伤口部位局部施用伤口愈合组合物，其中伤口愈合组合物包括以下至少一种：(a) 钙通道阻滞剂或其药学上可接受的盐或溶剂； (b) α-肾上腺素能拮抗剂或其药学上可接受的盐或溶剂； (c) 直接血管扩张剂或其药学上可接受的盐或溶剂；(d) 五型磷酸二酯酶抑制劑或其藥理上可接受的鹽或溶劑；及 (e) 痔瘡劑或其藥理上可接受的鹽或溶劑； (f) 主要真皮滲透劑或其藥理上可接受的鹽或溶劑：(g) 一种局部刺激剂或其药学上可接受的盐或溶液。
• Zelnick et al., Bulletin de la Societe Chimique de France, 1956, p. 888,892
  作者：Zelnick et al.

  DOI：——

  日期：——
• DE1014998
  申请人：——

  公开号：——

  公开（公告）日：——
• Graefe, Arzneimittel-Forschung/Drug Research, 1967, vol. 17, # 11, p. 1465 - 1467
  作者：Graefe

  DOI：——

  日期：——
• Advanced Formulations and Therapies for Treating Hard-to-Heal Wounds
  申请人：Kopacki Matthew H.

  公开号：US20190099426A1

  公开（公告）日：2019-04-04

  A method for healing a hard-to-heal wound including the steps of: topically administering a wound healing composition to a wounded area, wherein the wound healing composition includes, at least one of: (a) a medicament characterized as a calcium channel blocker or pharmaceutically acceptable salts or solvates thereof; (b) a medicament characterized as an alpha-adrenergic antagonist or pharmaceutically acceptable salts or solvates thereof; (c) a medicament characterized as a direct vasodilator or pharmaceutically acceptable salts or solvates thereof; and (d) a medicament characterized as a phosphodiesterase type five inhibitor or pharmaceutically acceptable salts or solvates thereof; and (e) a hemorrheologic agent or pharmaceutically acceptable salts or solvates thereof; (f) a primary dermal penetrating agent or pharmaceutically acceptable salts or solvates thereof: and (g) a topical stimulating agent or pharmaceutically acceptable salts or solvates thereof.